{"id":"W4206224214","doi":"10.1016/j.ajo.2022.01.004","title":"KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema","year":2022,"lang":"en","type":"article","venue":"American Journal of Ophthalmology","topic":"Retinal Diseases and Treatments","field":"Medicine","cited_by":168,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Ottawa","funders":"Allergan; Bayer Fund; AbbVie; Roche; Novartis Pharmaceuticals Corporation; Novartis","keywords":"Diabetic macular edema; Edema; Kestrel; Diabetic retinopathy; Clinical trial; Phases of clinical research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052957,0.001233876,0.002192065,0.0003371515,0.0003670358,0.001156962,0.0008486963,0.001683992,0.00323115],"category_scores_gemma":[0.003649519,0.0005854783,0.002125664,0.00027439,0.0007898592,0.001071161,0.0004538737,0.002610495,0.0005651569],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006029989,"about_ca_system_score_gemma":0.0008377231,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000441327,"about_ca_topic_score_gemma":0.00137931,"domain_scores_codex":[0.99829,0.001032698,0.0001327748,0.0001858995,0.0001717884,0.0001867505],"domain_scores_gemma":[0.9975103,0.0007245674,0.0007871687,0.0002138915,0.0001623827,0.0006015652],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9368918,0.009272914,0.002093456,0.0008886047,0.001813079,0.00006319154,0.0001047664,0.0003842875,0.007952127,0.00009432263,0.001208477,0.03923288],"study_design_scores_gemma":[0.8794562,0.1097463,0.007059013,0.0000645586,0.0009371158,0.0001115823,0.00002994191,0.000230201,0.001130533,0.00007342798,0.001136882,0.00002426079],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9779202,0.01565406,0.0006944792,0.001028729,0.0002788525,0.00169007,0.0009931376,0.00007136979,0.001669115],"genre_scores_gemma":[0.9896168,0.003985036,0.001253349,0.001145584,0.0002677275,0.001144421,0.001140865,0.00002262887,0.001423645],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0052957,"threshold_uncertainty_score":0.02800661,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04505861785045452,"score_gpt":0.3744115443462498,"score_spread":0.3293529264957953,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}